DYNAMICS OF THE POLYUNSATURATED FATTY ACIDS VALUES IN THE BLOOD OF CHRONIC HEART FAILURE PATIENTS

Aim. To assess the dynamics of levels of eicosapentaenoic (EPA), docosahexaenoic (DHA), arachidonic (AA) and linoleic (LA) fatty acids (FA), omega-3 index, relation of omega-3/omega-6 polyunsaturated FA (PUFA) in the blood of decompensated chronic heart failure (CHF) patients under the standard management.

Material and methods. The values of 22 FA were assessed in stable CHF (SCHF, n=12) and decompensated CHF (DCHF, n=24) and after decompensation treatment. The omega-3 index was calculated (relation of the sum of EPA and DHA to the sum of all FA) and relation of the sum of EPA and DHA to the sum of AA and LA.

Results. Values of EPA and DHA, omega-3 index in DCHF group were lower in SCHF (0,085 [0,06;0,17] vs 0,26 [0,15;0,4] mM/mL, p=0,0005; 0,37 [0,16;0,62] vs 0,84 [0,55;1,10] mM/mL, p=0,004; 1,11 [0,65;2,11] vs 2,44 [1,80;3,71]%, p=0,0008, respectively). After the treatment of DCHF, levels of EPA and DHA, omega-3 index raised, and reached 0,16 [0,11;0,21] mM/mL, p=0,0016; 0,46 [0,35;0,76] mM/mL, p=0,045; 1,74 [1,14;2,42]%, p=0,043, respectively. Statistically significant differences of AA and LA in the blood of SCHF and DCHF were not found. With the treatment, there was increase of AA value growth (3,40 [2,56;4,91] mM/mL, p=0,011) and tendency of LA increase (9,13 [5,08;11,28] mM/mL, p=0,09). Dynamics of omega-3/omega-6 relation witnessed the predominant part of omega-6 of PUFA in all participants, especially in DCHF. After treated fluid retention syndrome in patients this relation changed due to the raise of omega-3 PUFA.

Conclusion. In the DCHF there is significant increase of omega-3 index in the blood, concentrations of EPA and DHA. Standard therapy of CHF decompensation supports the increase of EPA, DHA, AA, omega-3 index. Mechanisms of the revealed PUFA dynamics in CHF patients, including the treatment outcomes, are subject for further investigation.

arachidonic acid, docosahexaenoic acid, linoleic acid, omega-3 index, polyunsaturated fatty acid, chronic heart failure, eicosapentaenoic acid

1. Mareev VYu, Ageev FT, Arutyunov GP, et al. SEHF, RSC and RSMSIM national guidelines on CHF diagnostics and treatment (fourth revision). Heart Failure Journal 2013; 14 (7): 379472. (In Russ.) Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность 2013; 14 (7): 379-472.

2. Wang C, Xiong B, Huang J. The Role of Omega3 Polyunsaturated Fatty Acids in Heart Failure: A MetaAnalysis of Randomised Controlled Trials. Nutrients 2016; 9 (1): E18.

3. Endo J, Arita M. Cardioprotective mechanism of omega3 polyunsaturated fatty acids. J Cardiol. 2016; 67 (1): 22-7.

4. Watanabe S, Yoshihisa A, Kanno Y, et al. Associations With Eicosapentaenoic Acid to Arachidonic Acid Ratio and Mortality in Hospitalized Heart Failure Patients. J Card Fail. 2016; 22 (12): 962-9.

5. Gavva EM, Tsaregorodtsev DA, Mamedov IS, Sulimov VA. Omega-3 index of erythrocytes and predictors of sudden cardiac death in patients with coronary heart disease and ventricular arrhythmias. Cardiovascular Therapy and Prevention 2012; 11 (4): 16-22. (In Russ.) Гавва Е. М., Царегородцев Д. А., Мамедов И. С., Сулимов В. А. Взаимосвязь омега-3-индекса эритроцитов с предикторами внезапной сердечной смерти у пациентов с ишемической болезнью сердца и желудочковыми аритмиями. Кардиоваскулярная терапия и профилактика 2012; 11 (4): 16-22.

6. Harris WS, Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Preventive Medicine 2004; 39: 212-20.

7. Toshiyuki Nagai, Yasuyuki Honda, Yasuo Sugano, et al. Circulating Omega6, But Not Omega3 Polyunsaturated Fatty Acids, Are Associated with Clinical Outcomes in Patients with Acute Decompensated Heart Failure. PLoS One. 2016; 11 (11): e0165841.

8. Mozaffarian D, Lemaitre RN, King IB, et al. Circulating longchain ω3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann Intern Med. 2011; 155 (3): 160-70.

9. Rupp H, Rupp TP, Alter P, Maisch B. Mechanisms involved in the differential reduction of omega3 And omega6 highly unsaturated fatty acids by structural heart disease resulting in “HUFA deficiency”. Can J Physiol Pharmacol. 2012; 90 (1): 55-73.

10. Mareev VYu, Mareev YuV. Methods of Prevention of Sudden Death in Chronic Heart Failure Kardiologiia. 2015; 55 (9): 72-83. (In Russ.) Мареев В. Ю., Мареев Ю. В. Методы профилактики внезапной сердечной смерти при хронической сердечной недостаточности. Кардиология. 2015; 55 (9): 72-83. DOI: 10.18565/cardio.2015.9.72-83

11. Hara M, Sakata Y, Nakatani D, et al. Low levels of serum n-3 polyunsaturated fatty acids are associated with worse heart failure-free survival in patients after acute myocardial infarction. Circ J. 2013; 77 (1): 153-62.

12. Alter P, Glück T, Figiel JH, et al. From Heart Failure to Highly Unsaturated Fatty Acid Deficiency and Vice Versa: Bidirectional Heart and Liver Interactions. Can J Cardiol. 2016; 32 (2): 217-25.

13. Kotjuzhinskaja SG, Vasyuk VL. The state of the fatty acid composition of blood lipids with hyperheparinemia. Actual problems of transport medicine 2014; 1 (35): 135-9. (In Russ.) Котюжинская С. Г., Васюк В. Л. Состояние жирнокислотного состава липидов крови при гипергепаринемии. Актуальные проблемы транспортной медицины 2014; 1 (35): 135-9.

14. Bays HE, Ballantyne CM, Doyle RT, et al. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016; 125: 57-64.

15. Chrysohoou C, Metallinos G, Georgiopoulos G, et al. Short term omega3 polyunsaturated fatty acid supplementation induces favorable changes in right ventricle function and diastolic filling pressure in patients with chronic heart failure; A randomized clinical trial. Vascul Pharmacol. 2016; 79: 43-50.